| Title |
Sphingosine kinase 1 as an anticancer therapeutic target
|
|---|---|
| Published in |
Drug Design, Development and Therapy, June 2015
|
| DOI | 10.2147/dddt.s83288 |
| Pubmed ID | |
| Authors |
Ying Gao, Fei Gao, Kan Chen, Mei-li Tian, Dong-li Zhao |
| Abstract |
The development of chemotherapeutic resistance is a major challenge in oncology. Elevated sphingosine kinase 1 (SK1) levels is predictive of a poor prognosis, and SK1 overexpression may confer resistance to chemotherapeutics. The SK/sphingosine-1-phosphate (S1P)/sphingosine-1-phosphate receptor (S1PR) signaling pathway has been implicated in the progression of various cancers and in chemotherapeutic drug resistance. Therefore, SK1 may represent an important target for cancer therapy. Targeting the SK/S1P/S1PR signaling pathway may be an effective anticancer therapeutic strategy, particularly in the context of overcoming drug resistance. This review summarizes our current understanding of the role of SK/S1P/S1PR signaling in cancer and development of SK1 inhibitors. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Unknown | 43 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 14 | 32% |
| Student > Ph. D. Student | 9 | 20% |
| Researcher | 4 | 9% |
| Student > Doctoral Student | 3 | 7% |
| Other | 3 | 7% |
| Other | 8 | 18% |
| Unknown | 3 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 12 | 27% |
| Biochemistry, Genetics and Molecular Biology | 10 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 11% |
| Chemistry | 4 | 9% |
| Medicine and Dentistry | 3 | 7% |
| Other | 4 | 9% |
| Unknown | 6 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2019.
All research outputs
#7,856,238
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#524
of 2,254 outputs
Outputs of similar age
#86,015
of 281,752 outputs
Outputs of similar age from Drug Design, Development and Therapy
#27
of 126 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,752 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 126 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.